{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:15:51Z","timestamp":1791825351207,"version":"4.3.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s00415-024-12807-1","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T12:17:48Z","timestamp":1734005868000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Factors affecting the diagnostic delay of myasthenia gravis"],"prefix":"10.1007","volume":"272","author":[{"given":"I. R.","family":"Marlet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. K.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. H.","family":"Axelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. K.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Vissing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Witting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"issue":"8","key":"12807_CR1","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.nmd.2021.05.007","volume":"31","author":"LK Andersen","year":"2021","unstructured":"Andersen LK, Aadahl M, Vissing J (2021) Fatigue, physical activity and associated factors in 779 patients with myasthenia gravis. Neuromuscul Disord NMD 31(8):716\u2013725. https:\/\/doi.org\/10.1016\/j.nmd.2021.05.007","journal-title":"Neuromuscul Disord NMD"},{"issue":"25","key":"12807_CR2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026457","volume":"100","author":"H Kim","year":"2021","unstructured":"Kim H, Oh SY (2021) Diagnostic yields and clinical features of ocular myasthenia gravis. Medicine (Baltimore) 100(25):e26457. https:\/\/doi.org\/10.1097\/MD.0000000000026457","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"12807_CR3","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.3390\/jcm10081736","volume":"10","author":"RT Rousseff","year":"2021","unstructured":"Rousseff RT (2021) Diagnosis of myasthenia gravis. J Clin Med 10(8):1736. https:\/\/doi.org\/10.3390\/jcm10081736","journal-title":"J Clin Med"},{"issue":"1","key":"12807_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/mus.24697","volume":"53","author":"JS Hansen","year":"2016","unstructured":"Hansen JS et al (2016) Mortality in myasthenia gravis: a nationwide population-based follow-up study in Denmark. Muscle Nerve 53(1):73\u201377. https:\/\/doi.org\/10.1002\/mus.24697","journal-title":"Muscle Nerve"},{"key":"12807_CR5","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","volume":"11","author":"K Lazaridis","year":"2020","unstructured":"Lazaridis K, Tzartos SJ (2020) Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics. Front Immunol 11:212. https:\/\/doi.org\/10.3389\/fimmu.2020.00212","journal-title":"Front Immunol"},{"issue":"10","key":"12807_CR6","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14(10):1023\u20131036. https:\/\/doi.org\/10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"issue":"11","key":"12807_CR7","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3390\/jcm10112235","volume":"10","author":"L Dresser","year":"2021","unstructured":"Dresser L, Wlodarski R, Rezania K, Soliven B (2021) Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med 10(11):2235. https:\/\/doi.org\/10.3390\/jcm10112235","journal-title":"J Clin Med"},{"issue":"1","key":"12807_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2122\/jml-2020-0145","volume":"14","author":"A-M Bubuioc","year":"2021","unstructured":"Bubuioc A-M, Kudebayeva A, Turuspekova S, Lisnic V, Leone MA (2021) The epidemiology of myasthenia gravis. J Med Life 14(1):7\u201316. https:\/\/doi.org\/10.2122\/jml-2020-0145","journal-title":"J Med Life"},{"issue":"5","key":"12807_CR9","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1212\/wnl.47.5.1233","volume":"47","author":"LH Phillips","year":"1996","unstructured":"Phillips LH, Torner JC (1996) Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology 47(5):1233\u20131238. https:\/\/doi.org\/10.1212\/wnl.47.5.1233","journal-title":"Neurology"},{"issue":"1","key":"12807_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1055\/s-2004-829593","volume":"24","author":"LH Phillips","year":"2004","unstructured":"Phillips LH (2004) The epidemiology of myasthenia gravis. Semin Neurol 24(1):17\u201320. https:\/\/doi.org\/10.1055\/s-2004-829593","journal-title":"Semin Neurol"},{"issue":"3","key":"12807_CR11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P et al (2021) International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 96(3):114\u2013122. https:\/\/doi.org\/10.1212\/WNL.0000000000011124","journal-title":"Neurology"},{"issue":"10","key":"12807_CR12","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1136\/jnnp.52.10.1121","volume":"52","author":"HJ Oosterhuis","year":"1989","unstructured":"Oosterhuis HJ (1989) The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry 52(10):1121\u20131127. https:\/\/doi.org\/10.1136\/jnnp.52.10.1121","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"12807_CR13","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1001\/archneur.1991.00530190081019","volume":"48","author":"FE Somnier","year":"1991","unstructured":"Somnier FE, Keiding N, Paulson OB (1991) Epidemiology of myasthenia gravis in Denmark. A longitudinal and comprehensive population survey. Arch Neurol 48(7):733\u2013739. https:\/\/doi.org\/10.1001\/archneur.1991.00530190081019","journal-title":"Arch Neurol"},{"issue":"7","key":"12807_CR14","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/acn3.51792","volume":"10","author":"C Zhang","year":"2023","unstructured":"Zhang C et al (2023) Mortality of myasthenia gravis: a national population-based study in China. Ann Clin Transl Neurol 10(7):1095\u20131105. https:\/\/doi.org\/10.1002\/acn3.51792","journal-title":"Ann Clin Transl Neurol"},{"issue":"7","key":"12807_CR15","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/j.1468-1331.2010.03017.x","volume":"17","author":"Z-F Mao","year":"2010","unstructured":"Mao Z-F, Mo X-A, Qin C, Lai Y-R, OldeHartman TC (2010) Course and prognosis of myasthenia gravis: a systematic review. Eur J Neurol 17(7):913\u2013921. https:\/\/doi.org\/10.1111\/j.1468-1331.2010.03017.x","journal-title":"Eur J Neurol"},{"issue":"9","key":"12807_CR16","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1080\/00207454.2016.1257993","volume":"127","author":"J Yang","year":"2017","unstructured":"Yang J, Liu C, Li T, Li C (2017) \u201cPrognosis of thymectomy in myasthenia gravis patients with thymus hyperplasia. Int J Neurosci 127(9):785\u2013789. https:\/\/doi.org\/10.1080\/00207454.2016.1257993","journal-title":"Int J Neurosci"},{"key":"12807_CR17","doi-asserted-by":"publisher","first-page":"1214041","DOI":"10.3389\/fneur.2023.1214041","volume":"14","author":"T Sobierajski","year":"2023","unstructured":"Sobierajski T, Lasek-Bal A, Krzystanek M, Gilhus NE (2023) Diagnosis and therapy of myasthenia gravis\u2014the patients\u2019 perspective: a cross-sectional study. Front Neurol 14:1214041. https:\/\/doi.org\/10.3389\/fneur.2023.1214041","journal-title":"Front Neurol"},{"issue":"1","key":"12807_CR18","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s40120-021-00312-w","volume":"11","author":"A Dragusin","year":"2022","unstructured":"Dragusin A et al (2022) Low fluctuation of symptoms may delay diagnosis of myasthenia gravis: a case series. Neurol Ther 11(1):481\u2013487. https:\/\/doi.org\/10.1007\/s40120-021-00312-w","journal-title":"Neurol Ther"},{"key":"12807_CR19","doi-asserted-by":"publisher","DOI":"10.12890\/2017_000785","author":"MS Mustafa","year":"2017","unstructured":"Mustafa MS, Marshal M, Ahern E, Crowley P (2017) Delayed diagnosis of atypical presentation of myasthenia gravis. Eur J Case Rep Intern Med. https:\/\/doi.org\/10.12890\/2017_000785","journal-title":"Eur J Case Rep Intern Med"},{"issue":"3","key":"12807_CR20","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/ana.410120303","volume":"12","author":"JJ Kelly","year":"1982","unstructured":"Kelly JJ, Daube JR, Lennon VA, Howard FM, Younge BR (1982) The laboratory diagnosis of mild myasthenia gravis. Ann Neurol 12(3):238\u2013242. https:\/\/doi.org\/10.1002\/ana.410120303","journal-title":"Ann Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12807-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12807-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12807-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T17:58:04Z","timestamp":1738173484000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12807-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["12807"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12807-1","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,12]]},"assertion":[{"value":"13 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors were funded by an unrestricted grant from UCB Biopharma. J. Vissing has been a consultant for Amicus Therapeutics, Arvinas, Biogen, Fulcrum Therapeutics, Genethon, Horizon Therapeutics, Lupin, ML Biopharma, Novartis Pharma AG, Regeneron, Roche, Sanofi Genzyme, Sarepta Therapeutics and UCB Pharma. He has received research, travel support and\/or speaker honoraria from Alexion Pharmaceuticals, argenx, Biogen, Edgewise Therapeutics, Fulcrum Therapeutics, Lupin, Sanofi Genzyme, and UCB Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"29"}}